Nyheder og presseoversigt
Nyheder og presseoversigt
Her kan du finde de seneste nyheder om Italfarmaco Nordics og virksomhedens presseanmeldelser.
2024 - September 6
Verdens Duchenne Bevidsthedsdag 2024
Den 7. september markeres World Duchenne Awareness Day (WDAD), en sygdom, hvor vi som virksomhed er særligt engagerede.
Corporate News
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
Press review
2024 – March 21
Business Wire
Italfarmaco receives FDA approval for givinostat in Duchenne muscular dystrophy (DMD)
March 21, 2024 - Business Wire
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
2024 – March 19
Business Wire
Italfarmaco Publishes in The Lancet Neurology results from Phase 3 EPIDYS Study in Duchenne Muscular Dystrophy (DMD)
March 19, 2024 - Business Wire
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
2023 – September 05
Business Wire
Italfarmaco Group Receives EMA Validation of Marketing Authorization Application for Givinostat in Duchenne Muscular Dystrophy
September 05, 2023 - Business Wire
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
2023 – June 29
Business Wire
Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review
June 29, 2023 - Business Wire
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
2022 – June 25
Business Wire
Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy
June 25, 2022 - Business Wire
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.
Corporate Press
Please kindly note that you are leaving the Italfarmaco Nordics website to connect with another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with local legislation.